JP7539151B2 - Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法 - Google Patents

Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法 Download PDF

Info

Publication number
JP7539151B2
JP7539151B2 JP2020535980A JP2020535980A JP7539151B2 JP 7539151 B2 JP7539151 B2 JP 7539151B2 JP 2020535980 A JP2020535980 A JP 2020535980A JP 2020535980 A JP2020535980 A JP 2020535980A JP 7539151 B2 JP7539151 B2 JP 7539151B2
Authority
JP
Japan
Prior art keywords
cancer
combination
compound
pharmaceutical composition
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020535980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510680A (ja
JPWO2019140324A5 (https=
JP2021510680A5 (https=
Inventor
ジャマル，スマヤフ
Original Assignee
イーエヌビー・セラピューティクス・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーエヌビー・セラピューティクス・インク filed Critical イーエヌビー・セラピューティクス・インク
Publication of JP2021510680A publication Critical patent/JP2021510680A/ja
Publication of JPWO2019140324A5 publication Critical patent/JPWO2019140324A5/ja
Publication of JP2021510680A5 publication Critical patent/JP2021510680A5/ja
Application granted granted Critical
Publication of JP7539151B2 publication Critical patent/JP7539151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020535980A 2018-01-12 2019-01-11 Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法 Active JP7539151B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616729P 2018-01-12 2018-01-12
US62/616,729 2018-01-12
PCT/US2019/013377 WO2019140324A1 (en) 2018-01-12 2019-01-11 Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation

Publications (4)

Publication Number Publication Date
JP2021510680A JP2021510680A (ja) 2021-04-30
JPWO2019140324A5 JPWO2019140324A5 (https=) 2022-02-07
JP2021510680A5 JP2021510680A5 (https=) 2022-02-07
JP7539151B2 true JP7539151B2 (ja) 2024-08-23

Family

ID=67212721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020535980A Active JP7539151B2 (ja) 2018-01-12 2019-01-11 Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法

Country Status (10)

Country Link
US (4) US10435434B2 (https=)
EP (1) EP3713571A4 (https=)
JP (1) JP7539151B2 (https=)
KR (1) KR102846292B1 (https=)
CN (1) CN111886010A (https=)
AU (1) AU2019206652B2 (https=)
CA (1) CA3087009A1 (https=)
EA (1) EA202091630A1 (https=)
MX (1) MX2020007293A (https=)
WO (1) WO2019140324A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695400B2 (en) 2015-08-03 2020-06-30 Enb Therapeutics, Inc. Compositions and methods for treating cancers associated with ETBR activation
AU2019206652B2 (en) * 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
CN114423425A (zh) * 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
EP4608447A1 (en) * 2022-10-28 2025-09-03 ENB Therapeutics, Inc. Methods for treating cancers associated with etbr activation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519355A (ja) 1997-10-08 2001-10-23 エス． セルバラージ ナイッカー， 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用
WO2015110593A1 (en) 2014-01-24 2015-07-30 Cecilia Naucler Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer
US20170035836A1 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4874780A (en) * 1987-03-11 1989-10-17 Norsk Hydro A.S. Anticancer compounds
US5496928A (en) 1990-06-07 1996-03-05 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
TW217417B (https=) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006019637A2 (en) 2004-07-07 2006-02-23 The Regents Of The University An intelligent nanomedicine integrating diagnosis and therapy
US20080102451A1 (en) 2006-10-31 2008-05-01 Abbott Laboratories Companion diagnostic assays for endothelin receptor antagonists
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US9289426B2 (en) 2007-03-21 2016-03-22 University Of Pennsylvania Methods and compositions for treating solid tumors and enhancing tumor vaccines
US8303974B2 (en) 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
CN102170908A (zh) 2008-08-29 2011-08-31 莱顿大学医学中心附属莱顿教学医院 向个体的肿瘤引流淋巴结递送cd40激动剂
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
ES2543280T3 (es) 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
US20140341916A1 (en) 2011-10-28 2014-11-20 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
US10233277B2 (en) 2012-03-02 2019-03-19 The Governing Council Of The University Of Toronto Polymeric nanoparticles useful in theranostics
WO2014025837A1 (en) 2012-08-06 2014-02-13 Board Of Regents, The University Of Texas System Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
RS61152B2 (sr) 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
JP7144935B2 (ja) 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
EP3746110A4 (en) 2018-03-30 2022-03-02 ENB Therapeutics, Inc. ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS AND USES
CN114423425A (zh) 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
US20200289495A1 (en) 2020-03-24 2020-09-17 Enb Therapeutics, Inc. Methods of inhibiting endothelin b receptor expressing tumor metastases
US20200268829A1 (en) 2020-03-24 2020-08-27 Enb Therapeutics, Inc. Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519355A (ja) 1997-10-08 2001-10-23 エス． セルバラージ ナイッカー， 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用
WO2015110593A1 (en) 2014-01-24 2015-07-30 Cecilia Naucler Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer
US20170035836A1 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAY, CL et al.，Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy，The Journal of Infectious Diseases，2017年，Vol. 215, No. 11，pp. 1725-1733

Also Published As

Publication number Publication date
US20190218251A1 (en) 2019-07-18
US12077604B2 (en) 2024-09-03
JP2021510680A (ja) 2021-04-30
US20190345197A1 (en) 2019-11-14
KR102846292B1 (ko) 2025-08-13
US11066442B2 (en) 2021-07-20
MX2020007293A (es) 2021-01-08
EP3713571A1 (en) 2020-09-30
WO2019140324A1 (en) 2019-07-18
CA3087009A1 (en) 2019-07-18
US10435434B2 (en) 2019-10-08
US20240360173A1 (en) 2024-10-31
US20210309694A1 (en) 2021-10-07
EA202091630A1 (ru) 2020-12-04
KR20200119246A (ko) 2020-10-19
CN111886010A (zh) 2020-11-03
AU2019206652A1 (en) 2020-07-16
EP3713571A4 (en) 2021-08-25
AU2019206652B2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
AU2024205010B2 (en) CSF1R inhibitors for use in treating cancer
JP7539151B2 (ja) Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法
TWI887465B (zh) 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法
US20210077562A1 (en) Etbr antagonist compounds, compositions, and uses
US20220265628A1 (en) Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
WO2021178789A1 (en) Methods of using rebastinib in the treatment of different cancerous disorders
EA046650B1 (ru) Дейтерированные соединения, композиции и способы для лечения рака, связанного с активацией etbr
RU2844734C1 (ru) Преимущественные терапии нарушений, опосредованных ikaros или aiolos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230301

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240805

R150 Certificate of patent or registration of utility model

Ref document number: 7539151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150